PAVmed Secures $7 Million in Private Placement to Advance Commercialization of Clinical Medical Products

VCBeat (WeChat ID: vcbeat) learned from foreign media sources on December 28 that Pavmed announced this week it had entered into an agreement with an investment firm to sell $7.8 million in senior secured convertible notes. The notes were issued at a discount of $725,000, resulting in net proceeds of $7 million. According to a report filed with the U.S. Securities and Exchange Commission (SEC), Maxim Group, which served as the placement agent for the transaction, received a fee of 6.5%.

PAVmed stated that, upon completion of the convertible note offering, it repaid the outstanding principal balance and all accrued interest on senior secured notes held by an existing bank lender, and paid Scopia Holdings $5 million in cash and issued 600,000 shares of common stock.

(Image source: PAVmed official website)

PAVmed is a pioneering medical device company that transitions innovative medical technologies from conceptualization to commercialization with unprecedented speed and capital efficiency. Founded and led by three successful medical device entrepreneurs, PAVmed boasts a mature business model. With a strong focus on capital efficiency and market speed, the company leverages meticulous project selection and refined business processes to bring products from concept to commercialization faster and with less capital than typical medical device companies.

The Company believes that medical devices have the potential to move from conceptualization to commercialization at a faster pace and with less capital investment. However, most medical device companies lack the structural or operational capacity to realize this potential. PAVmed’s business model significantly surpasses these industry benchmarks. PAVmed stated that a key factor in its success is its regulatory strategy, which focuses on identifying the narrowest and most efficient initial approval pathways.

PAVmed’s model integrates key business processes that leverage external resources, including low-cost and lightweight infrastructure, top-tier process outsourcing experts, leading process engineering specialists, and parallel development workflows. This approach enables us to operate as a larger organization while ensuring precise and efficient operations.

The Company believes that, regardless of the target specialty or clinical area, priority should be given to products with high profit margins and significant impact on attractive markets.

Minimally Invasive CarpX Device (Image Source: Pavmed Official Website)

Pavmed has a minimally invasive Carpx device for the treatment of carpal tunnel syndrome. The device allows doctors to relieve compression of the patient's median nerve without using surgical incisions. The company believes that Carpx can reduce costs by moving surgery from the operating room to a lighter environment, reducing postoperative pain, and accelerating patients' recovery to full activity.

According to Pavmed, traditional open surgery is effective but invasive. Endoscopic surgery is less invasive but technically challenging, costly, and associated with a high complication rate. Prior to endoscope insertion into the carpal tunnel, surgical incisions and some degree of surgical dissection are still required. In contrast, CarpX utilizes a balloon catheter equipped with bipolar radiofrequency cutting electrodes. Guided by ultrasound, this device positions an advanced wire within the carpal tunnel. Upon activation, it creates space within the catheter, ensures the nerve is protected from injury by the cutting electrodes, and decompresses the median nerve by dividing the transverse carpal ligament.

Earlier this year, the FDA organized a review of Pavmed’s application for its CarpX device, but no consensus was reached within the agency’s prescribed review period. To extend the review process, the FDA advised Pavmed to resubmit its application. Subsequently, in a filing with the SEC, Pavmed indicated that it had resubmitted the application in August.